Oncology
Kaposiform Hemangioendothelioma
3
Pipeline Programs↗
2
Active Trials↗
3
Companies Involved↗
Kaposiform Hemangioendothelioma is an early-stage landscape with 3 programs across 3 companies. The most active players are Veloxis Pharmaceuticals, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Prism Pharmaceuticals. 1 therapy is approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 22
Phase 3
No programs
Approved1
Analysis
Trial Status
7
clinical trials
Completed4 · 57%
Unknown status1 · 14%
Recruiting1 · 14%
Not yet recruiting1 · 14%
Clinical Trials
Trial Activity
7 trials
Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma
Completed·—·Phase 4·NCT04448873·30 enrolled
Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma
Completed·—·Phase 4·NCT04077515·92 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)